LoadingLoadingLoadingThe quick read
Latest quote·Oct 16
Net selling: insiders sold $30M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net buying of $30K to $100K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $30M and bought $0 of MRK stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. The largest was Zachary, Jennifer (EVP, General Counsel), who sold $10.7M. The latest filing was on Aug 13, 2026.
Rep. Maria Elvira Salazar (R) bought $15K to $50K on Aug 19, 2026, disclosed 21 days later. Rep. Maria Elvira Salazar (R) bought $15K to $50K on Aug 19, 2026, disclosed 21 days later. In total, 1 member disclosed 2 MRK trades with trade dates in the last 180 days, filed a median 21 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Qube Research
$134.2M
bought
Sells/Trims (2)
Balyasny
$210.8M
trimmed
Millennium
$164.9M
trimmed
No tracked top-trader positions in MRK right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Financial period
Q2 2026
Adjusted EPS
-$0.26 expected
Revenue
No reported revenue on record
Full Year 2026 guidance
$66.30B to $67.30B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | -$0.13 / -$0.26Yahoo Finance | +49.43% beat | Unavailable | Unavailable |
| Mar 31, 2026 | Apr 30, 2026 | -$1.28 / -$1.47Yahoo Finance | +13.15% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 3, 2026 | $2.04 / $2.01Yahoo Finance | +1.47% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 30, 2025 | $2.58 / $2.35Yahoo Finance | +9.85% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 29, 2025 | $2.13 / $2.03Alpha Vantage | +4.93% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 24, 2025 | $2.22 / $2.14Alpha Vantage | +3.74% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 4, 2025 | $1.72 / $1.67Alpha Vantage | +2.99% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | $1.57 / $1.57Alpha Vantage | +0.00% in line | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 18, 2026
EPS expected
$1.80 to $2.29
Revenue expected
16 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.18B | $16.32B | $16.29B | $16.61B |
| Cost of what it sold | $4.19B | $4.82B | $2.94B | $4.39B |
| Gross profit | $12.99B | $11.51B | $13.34B | $12.21B |
| What it spent | ||||
| Research and development | $3.55B | $2.50B | $12.56B | $9.74B |
| Sales and admin | $2.63B | $2.85B | $2.70B | $2.90B |
| Other operating costs | -$659.0M | — | — | $250.0M |
| Total operating expenses | $5.53B | $5.35B | $15.23B | $12.89B |
| What was left | ||||
| Operating profit | $7.46B | $6.16B | -$1.88B | -$683.0M |
| Interest on debt | $327.0M | $411.0M | $479.0M | $525.0M |
| Profit before tax | $6.75B | $3.42B | -$3.53B | -$683.0M |
| Tax | $958.0M | $458.0M | $709.0M | $654.0M |
| Net profit | $5.79B | $2.96B | -$4.24B | -$1.33B |
| EBITDA | $8.23B | $6.30B | -$2.02B | $1.43B |
This stock is in a strong uptrend.
Trend
Strong uptrend
80 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
VMS Asset Management Limited Makes New Investment in Merck & Co., Inc. $MRK
BullishOct 15Merck & Co., Inc. $MRK Stock Position Lessened by HBW Advisory Services LLC
Leans bullishOct 15Form 25-NSE Merck & Co., Inc. Filed by: NEW YORK STOCK EXCHANGE LLC
NeutralOct 15Strategy Asset Managers LLC Purchases 13,021 Shares of Moderna, Inc. $MRNA
Leans bullishOct 15Western Financial Corp CA Acquires 29,043 Shares of Merck & Co., Inc. $MRK
Leans bullishOct 15Merck & Co., Inc. $MRK Shares Sold by Godsey & Gibb Inc.
BullishOct 15Merck & Co. (NYSE:MRK): A Quality Investing Case With Strong ROIC but Revenue Growth Concerns
NeutralOct 15HALO Stock Climbs As Patent Win And Deals Lift Outlook
NeutralOct 14